Back to Results

A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN328 in Patients with Advanced Cancers Associated with Expression of Delta-Like Canonical Notch Ligand 3 (DLL3) Who Have Failed Standard Available Therapy

Study category: Cancer

Is this Study for You?

Let's Get Started!



Type of Study



University of Colorado Hospital

Principal Investigator
Jose Pacheco,  MD

Jose Pacheco, MD

Study ID

Protocol Number: 21-2992

More information available at NCT04471727

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers